TBPH Theravance Biopharma, Inc.
Healthcare$16.41+0.24%ClosedMarket Cap: $846.0M
As of 2026-05-26
Valuation
P/E (TTM)
8.05
PEG
0.03
P/B
2.90
P/S
7.71
EV/EBITDA
79.02
DCF Value
$-94.65
FCF Yield
31.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.4%
Operating Margin
0.1%
Net Margin
104.3%
ROE
43.8%
ROA
24.3%
ROIC
0.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $17.7M | 91.9% | $-8.3M | $-4.9M | $— | — |
| Q4 null | $45.9M | 96.7% | $17.6M | $61.0M | $— | — |
| FY null | $107.5M | 94.9% | $-13.2M | $105.9M | $— | — |
| Q3 null | $20.0M | 59.4% | $-6.5M | $3.6M | $— | — |
| Q2 null | $26.2M | 60.0% | $-2.7M | $54.8M | $— | — |
| Q1 null | $15.4M | 25.6% | $-14.4M | $-13.6M | $— | — |
| Q4 null | $18.8M | 100.0% | $-9.2M | $-15.5M | $— | — |
| FY null | $64.4M | 100.0% | $-46.9M | $-56.4M | $— | — |
| Q3 null | $16.9M | 45.1% | $-10.8M | $-12.7M | $— | — |
| Q2 null | $14.3M | 30.2% | $-15.7M | $-16.5M | $— | — |
| Q1 null | $14.5M | 38.2% | $-11.2M | $-11.7M | $— | — |
| Q4 2023 | $17.6M | 52.7% | $-6.2M | $-8.5M | $-0.17 | — |